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or 25% cost reduction versus innovator etanercept pricing, resulted in projected net 
budget-savings of (millions): (1) UK € 62–162, (2) France € 19–46, (3) Germany € 42–105, 
(4) Italy € 26–62 and (5) Spain € 16–37. Such savings, could potentially fund treatment 
for an additional 1,530 (UK) to 8,430 (Germany) patients with etanercept biosimilar 
over five-years. ConClusions: The introduction of an etanercept biosimilar could 
represent substantial cost-saving potential for healthcare systems in the EU5; budget-
impact was sensitive to market uptake-rates and discounts versus etanercept. These 
savings could be used to treat additional RA patients with a biosimilar.
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objeCtives: To estimate, from a Greek payer perspective, the budget impact of 
adopting certolizumab pegol (CZP) for the treatment of axial spondyloarthritis 
(axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-
axSpA). Methods: A budget impact model was locally adapted over a time horizon 
of 5 years, to estimate the impact of CZP taking shares from adalimumab (ADA), 
infliximab (IFX), etanercept (ETA), and golimumab (GOL), but not from conventional 
care (CC) in AS; and ADA but not CC in nr-axSpA. Data from AS and nr-axSpA popula-
tions in Greece were combined with data on market shares of available anti-TNFs 
and associated costs (i.e. medication acquisition and administration, healthcare vis-
its, laboratory and imaging tests) to estimate the budgetary consequences of CZP 
penetration. Data on the number of axSpA patients were derived from the National 
Statistical Service, published literature and expert opinion. It was assumed that the 
share of CZP will increase steadily from 5% in the first year to 13% in the fifth year 
of analysis in both populations, taking equal shares from the other biologicals. Drug 
and medical care reimbursement prices are net and reflect 2015 prices. Results: 
On average, the use of CZP is estimated to decrease the mean annual budget per AS 
patient by between € 95 to € 176 (0.9%–1.7%). On the other hand, CZP is anticipated to 
increase the annual budget per nr-axSpA patient by between € 809 to € 827 (8.6% to 
8.8%), as it costs slightly more than ADA. For the overall axSpA population, the average 
annual increase per patient ranges from € 342 to € 372 (3.4% to 3.7%), which is below 
a reimbursement threshold set by the main health insurance fund. ConClusions: 
The reimbursement of CZP for the treatment of axSpA patients in Greece will, on 
aggregate, result in a modest and acceptable increase in the total therapy cost.
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objeCtives: Biologics such as etanercept, can be efficacious in reducing disease 
activity in their authorised indications, but are considered costly. The objective of 
this study was to assess future budget-impact of introducing an etanercept biosimi-
lar in the EU5 for all licensed adult indications. Methods: A budget-impact model 
(BIM) was developed to estimate the impact of potentially introducing an etanercept 
biosimilar on the healthcare budgets in over a five-year horizon (2016-2020) from 
the payer’s perspective. Prevalence-based, incidence-based and country-specific 
model adaptations evaluate the impact of introducing an etanercept biosimilar to 
a segment of the anti-TNFs market that includes innovator etanercept and adali-
mumab for rheumatoid arthritis (RA), psoriatic arthritis (PsA) psoriasis (PsO) and 
ankylosing spondylitis (AS); comparing total costs for scenarios with and without 
the biosimilar. Patients naïve to biologics, stable on, or failing the first biologic were 
tracked under a set of conservative assumptions: (1) uptake of 5% to 40% from 
etanercept to the biosimilar; (2) anti-TNF price erosion of 5% per year; (3) unknown 
price of etanercept biosimilar – two discount scenarios versus etanercept (10%, 25%) 
were applied. Results: The hypothetical introduction of an etanercept biosimilar 
in the biologic treatment setting for scenarios with a 10% or 25% cost reduction 
compared with innovator etanercept results in projected net budget-savings of 
(millions): (1) UK € 111–284, (2) France € 35–81, (3) Germany € 76–187, (4) Italy € 46–111 
and (5) Spain € 28–65. Such savings, could be used to fund treatment for an addi-
tional 3,100 (UK) to 17,130 (Germany) patients with etanercept biosimilar over five-
years. ConClusions: The introduction of an etanercept biosimilar could represent 
substantial cost-saving potential for EU5 healthcare systems; budget-impact was 
sensitive to market uptake-rates and discounts versus etanercept. These savings 
could be used to treat additional patients with a biosimilar.
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objeCtives: To evaluate and compare the budget impact of tocilizumab intravenous 
(IV) and adalimumab subcutaneous as a 1L monotherapy for the 6-month treatment 
of patients with RA, in the Greek healthcare system Methods: A budget impact 
model was developed to evaluate the cost per response rate of the two therapeutic 
options. Clinical data were derived from a head-to-head trial (ADACTA) and referred 
to the efficacy endpoints ACR 70, DAS 28≤ 3.2 and DAS 28< 2.6. Cost and resource 
utilization data were obtained from official government sources (2014) and included 
the cost of drugs, consumables, human resources, hospital charges and patient’s 
time (productivity loss). Cost per response for both therapeutic options was esti-
mated for all three clinical endpoints from the hospital, health system and societal 
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objeCtives: To estimate the incremental total and per-patient budget impact of 
adopting certolizumab pegol (CZP) for the recently indicated treatment of active 
psoriatic arthritis (PsA) in Greece. Methods: A budget impact model was adapted 
from a third-party payer perspective (EOPYY) to delineate the financial implica-
tions of introducing CZP for the treatment of PsA alongside currently indicated 
biologic treatments, namely etanercept, infliximab, adalimumab, golimumab, and 
ustekinumab, over the next 5 years (2014–2018). The model framework considered 
market share scenarios with and without CZP, and directly reimbursed costs of 
treatment and disease management, applied to the prevalent and eligible Greek 
patient population. Quarterly treatment discontinuation was geared to enable 
tracking of patients, so that the model could apply different costs to patients at 
different stages of treatment. Costs pertaining to drug acquisition, administration 
and monitoring were included for both the induction and maintenance years of 
patients’ treatment and corresponded to current costing year. Resource unit costs 
and epidemiological data were retrieved from officially published sources. The 
measured outcomes were incremental costs per treated patient per year (PTPPY) 
and total budget impact, calculated by comparing the respective patient and 
total budget expenditures with and without CZP in the market share mix scenar-
ios. Results: The incremental total and PTPPY costs resulting from the addition 
of CZP to the original treatment mix were estimated at -€ 2,036,848 (-1.76%) and 
-€ 859 respectively, over a 5-year time horizon. On average, annual cost-savings 
of € 407,370 (-1.76%) and € 172 were observed for both outcomes respectively. In 
each model, yearly cost-savings were yielded and 2018 was the year with the 
highest total cost-savings for EOPYY (€ 512,296 [-2.2%]). Cost-savings were driven 
by reduced drug and administration costs. ConClusions: The inclusion of CZP 
for active PsA treatment was predicted to be associated with short- and long-term 
cost-savings in Greece.
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objeCtives: To analyze the budgetary impact of different scenario of ten-
ders between the branded infliximab (BRANDED-INFLIX) and its biosimilars 
(BIOSIM-INFLIX) that could be implemented in the 37 public hospitals of Paris 
(AP-HP). Methods: Data collected: i) branded infliximab expenditures over the 
2012-2014 period; ii) 2014 medical information from PMSI hospital database (French 
medical information system program) to determine for which therapeutic indica-
tions the patients were treated with infliximab (gastroenterology, rheumatology, 
dermatology or others) by distinguishing infliximab-naïve patients (INFLIX-NAÏVE) 
and infliximab-experienced patients (INFLIX-EXPERIENCED). Three scenarios have 
been considered for the budget impact analysis: tender between BRANDED-INFLIX 
and BIOSIM-INFLIX to list only one infliximab in the hospital drug formulary with a 
hypothetical price decline of 20% (S1) or 30% (S2); tender between BRANDED-INFLIX 
and BIOSIM-INFLIX only for INFLIX-NAÏVE and no tender for INFLIX-EXPERIENCED 
who remain treated by BRANDED-INFLIX with a price decline of 20% and a propor-
tion of INFLIX-NAÏVE treated by BIOSIM-INFLIX of 10% (S3). Results: The branded 
infliximab represented € 42.1 million expenditures in 2014 compared to € 38.1 and 
€ 33.6 million in 2013 and in 2012 respectively. In 2014, 5483 patients were treated 
with the branded infliximab for several therapeutic indications: gastroenterology 
(61.9%), rheumatology (26.4%), dermatology (1.4%) and others (10.3%). The propor-
tions of INFLIX-NAÏVE by indication were: 35.9% in rheumatology, 32.5% in gastro-
enterology, 40.3% in dermatology and 42.8% in other indications. Over 3 years, S1 
would generate savings of € 22.8 million and S2 would save € 34.2 million, whereas 
with S3 the savings would amount to € 7.3 million (€ 4.5 million in gastroenterol-
ogy, € 2.1 million in rheumatology, € 0.1 in dermatology and € 0.6 in other indica-
tions). ConClusions: If the Committee on Medicinal Products (COMED) of AP-HP 
decides to implement tenders between BRANDED-INFLIX and BIOSIM-INFLIX the 
savings will be largely dependent on the scope of these tenders. These results could 
be considered by the COMED in its decision-making process.
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objeCtives: Rheumatoid arthritis (RA) has considerable impact on physical function 
and reduces quality of life. Biologics, such as etanercept, can be efficacious in reducing 
disease activity in their authorised indications. However, these treatment options can 
be very costly and present economic pressures on healthcare funding. The objective 
of this study was to assess budget-impact of introducing an etanercept biosimilar in 
the five largest European countries (EU5). Methods: A budget-impact model (BIM) 
was developed to estimate the impact of the hypothetical introduction of an etaner-
cept biosimilar on the healthcare budgets in EU5 over a five-year horizon (2016-2020) 
from the payer’s perspective. Prevalence-based, incidencebased and country-specific 
model adaptations evaluate the impact of introducing an etanercept biosimilar to a 
segment of the anti-TNF market that includes innovator etanercept and adalimumab; 
comparing total costs for scenarios with and without a biosimilar. Patients naïve to 
biologics, on stable treatment and failing the first biologic were tracked in the model 
under a set of conservative assumptions: (1) uptake of 5% to 40% (2016-2020) from 
etanercept to the biosimilar; (2) anti-TNF price-erosion of 5% per year; (3) unknown 
price of etanercept biosimilar – discount scenarios versus etanercept (10%, 25%) were 
applied. Results: The theoretical introduction of an etanercept biosimilar with a 10% 
